Medios AG · ISIN: DE000A1MMCC8 · EQS - Company News

Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins

Press release   Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins EBITDA pre1 reaches €24.6 million (+42.9%) in the third quarter of 2024, setting a new record EBITDA pre1 margin of 5.0% in the third quarter of 2024 Patient-Specific Therapies segment grows by more than 10% in EBITDA pre1 compared to the same quarter of the previous year Revenue in the nine-month period of 2024 up 4.2%, EBITDA pre1 up 20.6% Cash flow from operating activities signif...

XETR:ILM1 Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Medios AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (2)
Short Selling (DE) (1)
Short Selling (UK) (0)
12 November 2024 08:41AM
Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins
DE000A1MMCC8
Press release   Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins EBITDA pre1 reaches €24.6 million (+42.9%) in the third quarter of 2024, setting a new record EBITDA pre1 margin of 5.0% in the third quarter of 2024 Patient-Specific Therapies segment grows by more than 10% in EBITDA pre1 compared to the...
Medios AG
About the publication
14 August 2024 02:51PM
Annual General Meeting resolves to expand the Supervisory Board to five members
DE000A1MMCC8
Press release Medios AG: Annual General Meeting resolves to expand the Supervisory Board to five members Berlin, August 14, 2024 – The shareholders of Medios, a leading provider of Specialty Pharma in Europe, today approved all but two of the resolutions proposed by the Executive Board and Supervisory Board at the Annual General Meeting. A total ...
Medios AG
About the publication
13 August 2024 07:43AM
Medios AG continues its growth trajectory in the first half of 2024 and records disproportionately high increase in earnings
DE000A1MMCC8
Press release Medios AG continues its growth trajectory in the first half of 2024 and records disproportionately high increase in earnings Revenue increases by 6.3% and EBITDA pre1 by 7.3% in the first half of the year Cash flow from operating activities increases significantly to €34.0 million Acquisition of Ceban successfully completed in Jun...
Medios AG
About the publication
05 August 2024 10:32AM
Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President
DE000A1MMCC8
Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President Berlin, August 5, 2024 – Medios AG (“Medios“), a leading provider of Specialty Pharma in Europe, strengthens its activities in the field of Advanced Therapies and appoints Dr. Andreas Schmiede as Vice President Advanced Therapies. The entry into the Advan...
Medios AG
About the publication
01 July 2024 09:32AM
Medios hosts symposium on 'Security of supply”
DE000A1MMCC8
EQS-Media / 01.07.2024 / 09:32 CET/CEST Press release“Hauptstadtkongress 2024”: Medios hosts symposium on "Security of supply” Berlin, July 01, 2024 – Medios AG, a leading provider of Specialty Pharma in Europe, was represented for the first time at the “Hauptstadtkongress” (Capital Congress) in Berlin, which took place from June 26 to June 2...
Medios AG
About the publication
20 June 2024 10:02AM
Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A.
DE000A1MMCC8
Press Release Medios AG: Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A. Berlin, June 20, 2024 – Medios, a leading provider of Specialty Pharma in Europe, was today informed that Manfred Schneider has reallocated all of his shares in Medios AG. Schneider’s shares, which corresponds to a total of 14.9% of Medios’...
Medios AG
About the publication
07 June 2024 10:28AM
Hauck & Aufhäuser starts coverage of Medios AG with buy recommendation and price target of €23.00
DE000A1MMCC8
Press Release Hauck & Aufhäuser starts coverage of Medios AG with buy recommendation and price target of €23.00 Berlin, June 7, 2024 – Hauck & Aufhäuser Investment Banking initiated coverage of Medios AG yesterday and recommended the shares as a “buy”. The price target is €23.00 and thus around 55 percent above the Xetra closing price on ...
Medios AG
About the publication
06 June 2024 11:32AM
Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe
DE000A1MMCC8
Press release Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe Berlin, June 06, 2024 – Medios, a leading provider of Specialty Pharma in Europe, has completed the acquisition of Ceban Pharmaceuticals B.V. (“Ceban”), a fast-growing, leading pharmaceutical compounding platform with operati...
Medios AG
About the publication
06 June 2024 11:32AM
Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe
DE000A1MMCC8
Press release Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe Berlin, June 06, 2024 – Medios, a leading provider of Specialty Pharma in Europe, has completed the acquisition of Ceban Pharmaceuticals B.V. (“Ceban”), a fast-growing, leading pharmaceutical compounding platform with operati...
Medios AG
About the publication
07 May 2024 07:31AM
Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance
DE000A1MMCC8
Press release   Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance   Revenue increases by 5.8% to €456.2 million in the first quarter Cash flow from operating activities increases to €43.4 million Closing of the Ceban acquisition planned for May 2024 Guidance 2024 confirmed: Significant incr...
Medios AG
About the publication
06 May 2024 02:19PM
Constantijn van Rietschoten appointed Executive Board member for International Markets
DE000A1MMCC8
Medios AG: Constantijn van Rietschoten appointed Executive Board member for International Markets Berlin, May 6, 2024 – The Supervisory Board of Medios AG ("Medios") has appointed Constantijn van Rietschoten as member to the Company's Executive Board with effect from May 1, 2024. In his new role as Chief International Markets, van Rietschoten, who ...
Medios AG
About the publication
27 March 2024 07:54AM
Medios achieves double-digit growth in 2023 – Positive outlook for 2024
DE000A1MMCC8
Press release Medios achieves double-digit growth in 2023 – Positive outlook for 2024 Berlin, March 27, 2024 - Medios AG ("Medios"), the leading provider of specialty pharma solutions in Germany, once again grew strongly in the 2023 financial year. From January to December 2023, consolidated revenue increased by 10.8% to around €1.8 billion (prev...
Medios AG
About the publication
18 March 2024 08:46PM
Medios acquires Dutch market leader in pharmaceutical compounding services
DE000A1MMCC8
Medios acquires Dutch market leader in pharmaceutical compounding servicesImportant first step in building the leading European Specialty Pharma platform – Mid-term targets to be reached already in 2025 Berlin, March 18, 2024 – Medios, the leading provider of Specialty Pharma Solutions in Germany, today announced the acquisition of Ceban Pharmaceu...
Medios AG
About the publication
18 March 2024 08:41PM
Medios acquires Dutch market leader in pharmaceutical compounding services
DE000A1MMCC8
Medios acquires Dutch market leader in pharmaceutical compounding services Berlin, March 18, 2024 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in Germany, acquires Ceban Pharmaceuticals B.V. ("Ceban"), a fast-growing pharmaceutical compounding platform operating in the Netherlands, Belgium and Spain. With the combinat...
Medios AG
About the publication
01 February 2024 10:46AM
Supervisory Board extends contracts with members of the Executive Board Mi-Young Miehler and Christoph Prußeit
DE000A1MMCC8
Press Release Medios AG: Supervisory Board extends contracts with members of the Executive Board Mi-Young Miehler and Christoph Prußeit Berlin, February 1, 2024 – The Supervisory Board of Medios AG ("Medios") has decided to extend the existing Executive Board contracts of Mi-Young Miehler (Chief Operating Officer / COO) and Christoph Prußeit (Chi...
Medios AG
About the publication
14 November 2023 07:25AM
Medios records strongest quarter in the Company's history
DE000A1MMCC8
Press release Medios records strongest quarter in the Company's history Financials Q3 2023 vs. Q3 2022: Revenue increases by 16.9% to €489.9 million EBITDA pre1 increases by 12.7% to €17.2 million Forecast for the full year 2023 specified Berlin, November 14, 2023 – Medios, the leading provider of Specialty Pharma Solutions in Germany, once ag...
Medios AG
About the publication
24 October 2023 10:00AM
Strong operating cash flow – record figures as expected also for revenue and earnings in the third quarter of 2023
DE000A1MMCC8
Press release Medios AG: Strong operating cash flow – record figures as expected also for revenue and earnings in the third quarter of 2023 Financials Q3 2023 vs. Q3 2022: Revenue up 16.9% to €489.9 million EBITDA pre1 up 12.2% to €17.2 million Berlin, October 24, 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions i...
Medios AG
About the publication
14 August 2023 07:53AM
achieves further growth in the first half of 2023 and expects strong third quarter
DE000A1MMCC8
Press release Medios AG achieves further growth in the first half of 2023 and expects strong third quarter Revenue growth of around 8% with increases in both operating business segments Strong third quarter of 2023 expected Forecast for 2023 confirmed: Sustained revenue and earnings growth Berlin, August 14, 2023 – Medios AG ("Medios"), the lea...
Medios AG
About the publication
21 June 2023 03:01PM
Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board
DE000A1MMCC8
Press release   Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board Berlin, June 21, 2023 – The shareholders of Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, have approved the resolutions proposed by the Executive Board and the Supervisory ...
Medios AG
About the publication
21 June 2023 03:01PM
Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board
DE000A1MMCC8
Press release   Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board Berlin, June 21, 2023 – The shareholders of Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, have approved the resolutions proposed by the Executive Board and the Supervisory ...
Medios AG
About the publication
19 June 2023 11:04AM
Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH
DE000A1MMCC8
Press release Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH Utilization of synergy effects by concentrating blister activities at one site in southern Germany Measure implemented as part of the adjusted growth strategy Berlin, June 19, 2023 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solut...
Medios AG
About the publication
19 June 2023 11:04AM
Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH
DE000A1MMCC8
Press release Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH Utilization of synergy effects by concentrating blister activities at one site in southern Germany Measure implemented as part of the adjusted growth strategy Berlin, June 19, 2023 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solut...
Medios AG
About the publication
31 May 2023 10:00AM
Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
DE000A1MMCC8
Press release Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch Berlin, May 31, 2023 – The Supervisory Board of Medios AG ("Medios") has decided to extend the existing Executive Board contract of Falk Neukirch (Chief Financial Officer/CFO) ahead of schedule until April 30, 2026. Falk Neukirch has already be...
Medios AG
About the publication
31 May 2023 10:00AM
Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
DE000A1MMCC8
Press release Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch Berlin, May 31, 2023 – The Supervisory Board of Medios AG ("Medios") has decided to extend the existing Executive Board contract of Falk Neukirch (Chief Financial Officer/CFO) ahead of schedule until April 30, 2026. Falk Neukirch has already be...
Medios AG
About the publication
11 May 2023 07:40AM
starts successfully into the 2023 financial year
DE000A1MMCC8
Press release Medios AG starts successfully into the 2023 financial year   Start of the 2023 financial year with new revenue record in the first quarter Significant expansion of compounding capacities and extension of sales network Management strengthened with international expertise Outlook for 2023 confirmed: Sustainable growth in revenue a...
Medios AG
About the publication
11 May 2023 07:40AM
Medios AG: starts successfully into the 2023 financial year
DE000A1MMCC8
Press release Medios AG starts successfully into the 2023 financial year   Start of the 2023 financial year with new revenue record in the first quarter Significant expansion of compounding capacities and extension of sales network Management strengthened with international expertise Outlook for 2023 confirmed: Sustainable growth in revenue a...
Medios AG
About the publication
30 March 2023 07:54AM
Medios AG expects continued growth after record year in 2022 and plans further increase in profit margin
DE000A1MMCC8
Press release Medios AG expects continued growth after record year in 2022 and plans further increase in profit margin Record year 2022 with double-digit percentage increase in revenue and disproportionate earnings growth Significant expansion of sales network and manufacturing capacity Presentation of adjusted growth strategy Revenue growth ...
Medios AG
About the publication
30 March 2023 07:54AM
Medios AG expects continued growth after record year in 2022 and plans further increase in profit margin
DE000A1MMCC8
Press release Medios AG expects continued growth after record year in 2022 and plans further increase in profit margin Record year 2022 with double-digit percentage increase in revenue and disproportionate earnings growth Significant expansion of sales network and manufacturing capacity Presentation of adjusted growth strategy Revenue growth ...
Medios AG
About the publication
22 February 2023 11:06AM
Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023
DE000A1MMCC8
Press release   Medios AG: Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023   Preliminary figures 2022 and outlook for 2023 Consolidated revenue 2022 of around €1.6 billion at upper end of guidance EBITDA pre1 2022 rises by 43% to around €55 million with simultaneous significant improvement i...
Medios AG
About the publication
22 February 2023 11:06AM
Medios AG: Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023
DE000A1MMCC8
Press release   Medios AG: Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023   Preliminary figures 2022 and outlook for 2023 Consolidated revenue 2022 of around €1.6 billion at upper end of guidance EBITDA pre1 2022 rises by 43% to around €55 million with simultaneous significant improvement i...
Medios AG
About the publication
10 January 2023 11:28AM
Successful completion of the acquisition of bbw – Significant expansion of compounding volume
DE000A1MMCC8
Press release Medios AG: Successful completion of the acquisition of bbw – Significant expansion of compounding volume Berlin, January 10, 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, has successfully completed the acquisition of the pharmaceutical manufacturing company Blisterzentrum Baden-Württembe...
Medios AG
About the publication
24 November 2022 08:00AM
Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022
DE000A1MMCC8
Press release Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022 Strengthening the core business in Germany Expansion of the compounding business into further European countries planned Expansion of the Patient-Specific Therapies segment by entering into the manufacture of personalized medicine (inc...
Medios AG
About the publication
24 November 2022 08:00AM
Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022
DE000A1MMCC8
Press release Medios AG presents growth strategy and announces medium-term targets at Capital Markets Day 2022 Strengthening the core business in Germany Expansion of the compounding business into further European countries planned Expansion of the Patient-Specific Therapies segment by entering into the manufacture of personalized medicine (inc...
Medios AG
About the publication
22 November 2022 01:06PM
Medios AG: Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing
DE000A1MMCC8
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014   Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing Berlin, November 22, 2022 – Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH (...
Medios AG
About the publication
22 November 2022 01:06PM
Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing
DE000A1MMCC8
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014   Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing Berlin, November 22, 2022 – Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH (...
Medios AG
About the publication
10 November 2022 07:48AM
Medios AG continues growth course in the first nine months of 2022 – guidance for the 2022 financial year confirmed
DE000A1MMCC8
Press release Medios AG continues growth course in the first nine months of 2022 – guidance for the 2022 financial year confirmed   Strong inorganic and organic growth; seventh record quarter in a row Operating cash flow positive in both the third quarter of 2022 and the first nine months of the year Significant increase in capacity for compou...
Medios AG
About the publication
10 November 2022 07:48AM
Medios AG continues growth course in the first nine months of 2022 – guidance for the 2022 financial year confirmed
DE000A1MMCC8
Press release Medios AG continues growth course in the first nine months of 2022 – guidance for the 2022 financial year confirmed   Strong inorganic and organic growth; seventh record quarter in a row Operating cash flow positive in both the third quarter of 2022 and the first nine months of the year Significant increase in capacity for compou...
Medios AG
About the publication
27 October 2022 10:20AM
Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory
DE000A1MMCC8
Press release Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory Berlin, October 27, 2022 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, yesterday received the manufacturing permit for the new GMP (Good Manufacturing Practice) clean room labo...
Medios AG
About the publication
27 October 2022 10:20AM
Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory
DE000A1MMCC8
Press release Medios AG significantly expands compounding capacity at Berlin site – manufacturing permit granted for new laboratory Berlin, October 27, 2022 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, yesterday received the manufacturing permit for the new GMP (Good Manufacturing Practice) clean room labo...
Medios AG
About the publication
11 August 2022 07:37AM
Strong growth in the first half of 2022
DE000A1MMCC8
Press release   Medios AG continues record course: Strong growth in the first half of 2022   Revenue increase of around 25% – Strong inorganic and organic growth Profit margins significantly and sustainably improved, sixth consecutive record quarter Operating cash flow positive in both the second quarter of 2022 and the first half of 2022 Fo...
Medios AG
About the publication
11 August 2022 07:37AM
Medios AG continues record course: Strong growth in the first half of 2022
DE000A1MMCC8
Press release   Medios AG continues record course: Strong growth in the first half of 2022   Revenue increase of around 25% – Strong inorganic and organic growth Profit margins significantly and sustainably improved, sixth consecutive record quarter Operating cash flow positive in both the second quarter of 2022 and the first half of 2022 Fo...
Medios AG
About the publication
01 August 2022 10:45AM
Contract of CEO Matthias Gaertner extended ahead of schedule
DE000A1MMCC8
Press release Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule Berlin, August 01, 2022 – The Supervisory Board of Medios AG ("Medios") and the Chief Executive Officer (CEO) Matthias Gaertner have agreed to extend the existing Executive Board contract prematurely until January 31, 2025. Matthias Gaertner has been a member of...
Medios AG
About the publication
01 August 2022 10:45AM
Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule
DE000A1MMCC8
Press release Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule Berlin, August 01, 2022 – The Supervisory Board of Medios AG ("Medios") and the Chief Executive Officer (CEO) Matthias Gaertner have agreed to extend the existing Executive Board contract prematurely until January 31, 2025. Matthias Gaertner has been a member of...
Medios AG
About the publication
21 June 2022 02:38PM
Medios AG successfully holds Annual General Meeting 2022
DE000A1MMCC8
Press ReleaseMedios AG successfully holds Annual General Meeting 2022 Modernization of the Company's Articles of Association approved Compensation report approved New Stock Option Plan 2022 adopted Berlin, June 21, 2022 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in Germany, today successfully held its 2022 Annual ...
Medios AG
About the publication
11 May 2022 07:32AM
Medios AG: Revenue and earnings at record levels in the first quarter
DE000A1MMCC8
Press ReleaseMedios AG: Revenue and earnings at record levels in the first quarter Double-digit revenue growth and disproportionately high EBITDA pre1 increase Acquisition of NewCo Pharma Group: Significant strengthening of market position in manufacturing Outlook 2022 confirmed: Significant and sustainable increase in revenue and earnings expec...
Medios AG
About the publication
29 March 2022 08:02AM
Medios AG: Record year 2021 and positive outlook for 2022
DE000A1MMCC8
Press ReleaseMedios AG: Record year 2021 and positive outlook for 2022 Significant increase in revenue and earnings in the 2021 financial year Still significant growth expected for the 2022 financial year Berlin, March 29, 2022 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, today published its Annual Report...
Medios AG
About the publication
03 March 2022 12:08PM
Medios AG: Revenue expectation for 2021 exceeded - Significant growth planned for 2022
DE000A1MMCC8
Press ReleaseMedios AG: Revenue expectation for 2021 exceeded - Significant growth planned for 2022 Preliminary consolidated revenue of well over €1.3 billion better than expected EBITDA pre1 in line and EBT pre1 above forecast Forecast 2022: Revenue growth in the range of 6.8% - 17.9% and increase in EBITDA pre1 in the range of 35.3% - 50.9% Be...
Medios AG
About the publication
03 March 2022 12:05PM
Medios AG exceeds revenue and EBT pre1 forecasts for financial year 2021 - Executive Board optimistic for financial year 2022
DE000A1MMCC8
Medios AG exceeds revenue and EBT pre1 forecasts for financial year 2021 - Executive Board optimistic for financial year 2022 Berlin, March 3, 2022 - Due to stronger than expected organic growth, Medios AG ("Medios") has slightly exceeded its revenue and EBT pre1 forecasts for the financial year 2021. According to preliminary calculations (IFRS), ...
Medios AG
About the publication
More Medios AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 2 19th August 2024 van Rietschoten, Constantijn DD
Short Seller (DE) 1 2nd August 2024 JPMorgan Asset Management (UK) Ltd SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN